Overview

A Study of PLB-002 in Advanced Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Primelink BioTherapeitics(ShenZhen) Limited